36
Participants
Start Date
April 3, 2018
Primary Completion Date
June 3, 2019
Study Completion Date
June 3, 2019
Desvenlafaxine
Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
RECRUITING
Corporació Sanitària Parc Taulí, Sabadell
Lead Sponsor
Collaborators (1)
Pfizer
INDUSTRY
Corporacion Parc Tauli
OTHER